Sionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 875 Shares

December 20, 2025 by InsiderTrades.com

Key Points

OrbiMed Advisors LLC sold 875 shares of Sionna on Dec. 19 at an average price of $44.49 as part of a series of small disposals (including sales on Dec. 17–18 and Nov. 24–26); the transactions reduced its stake by only ~0.02% and it still holds about 3.595 million shares (≈$160M).
Sionna trades with a market cap of about $1.89 billion and was near its 1‑year high (~$45); analysts are mixed but show a consensus "Moderate Buy" with an average price target of $40.33.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Orbimed Advisors Llc sold 875 shares of the firm's stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $44.49, for a total transaction of $38,928.75. Following the completion of the sale, the director owned 3,595,011 shares in the company, valued at $159,942,039.39. This represents a 0.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Orbimed Advisors Llc also recently made the following trade(s):

On Thursday, December 18th, Orbimed Advisors Llc sold 100 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total transaction of $4,449.00.
On Wednesday, December 17th, Orbimed Advisors Llc sold 900 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.50, for a total transaction of $40,050.00.
On Wednesday, November 26th, Orbimed Advisors Llc sold 1,600 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $71,184.00.
On Tuesday, November 25th, Orbimed Advisors Llc sold 11,890 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.60, for a total transaction of $530,294.00.
On Monday, November 24th, Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.54, for a total value of $4,212,726.82.

Sionna Therapeutics Price Performance

Sionna Therapeutics stock opened at $42.37 on Friday. The stock has a market capitalization of $1.89 billion and a price-to-earnings ratio of -8.70. Sionna Therapeutics, Inc. has a 1-year low of $7.26 and a 1-year high of $45.00. The business has a fifty day moving average price of $38.80 and a 200-day moving average price of $27.25.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.06.

Sionna Therapeutics News Roundup

Here are the key news stories impacting Sionna Therapeutics this week:

Positive Sentiment: Senior insiders and institutional holders still retain very large stakes (reported holdings ~3.596M shares each, valued ~ $160M), which signals continued alignment with long‑term performance and limits the risk of a meaningful shift in control. SEC filing
Negative Sentiment: Director Peter A. Thompson sold a total of 1,875 SION shares across Dec. 17–19 at an average price ~ $44.49–44.50 (proceeds ≈ $83.4k). Each sale is small relative to his stake (ownership dipped ~0.03%), but the filings can prompt negative short‑term sentiment. SEC filing
Negative Sentiment: OrbiMed Advisors LLC (reported as a director-level holder) executed the same pattern of sales (875, 100 and 900 shares on Dec. 17–19) at similar prices, reducing its position by ~0.02–0.03%. Like the individual sales, the absolute size is small versus the owner’s remaining stake but likely contributes to today’s downside pressure. SEC filing

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. BTIG Research assumed coverage on shares of Sionna Therapeutics in a research report on Wednesday, November 19th. They issued a "buy" rating and a $50.00 price objective for the company. Raymond James Financial reiterated a "strong-buy" rating on shares of Sionna Therapeutics in a research note on Wednesday, November 5th. Royal Bank Of Canada reissued an "underperform" rating and issued a $24.00 target price on shares of Sionna Therapeutics in a research report on Monday, December 1st. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Sionna Therapeutics in a research report on Monday. Finally, Jones Trading initiated coverage on Sionna Therapeutics in a report on Monday, September 8th. They issued a "buy" rating and a $46.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Sionna Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $40.33.

Read Our Latest Research Report on SION

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Siren L.L.C. acquired a new position in Sionna Therapeutics during the first quarter valued at $3,400,000. Zimmer Partners LP purchased a new position in shares of Sionna Therapeutics during the 1st quarter valued at about $2,484,000. Goldman Sachs Group Inc. acquired a new position in shares of Sionna Therapeutics in the 1st quarter valued at about $667,000. Alyeska Investment Group L.P. purchased a new stake in shares of Sionna Therapeutics in the first quarter worth about $1,948,000. Finally, Prudential Financial Inc. grew its holdings in Sionna Therapeutics by 114.6% during the second quarter. Prudential Financial Inc. now owns 135,185 shares of the company's stock worth $2,345,000 after acquiring an additional 72,185 shares during the period.

About Sionna Therapeutics

(Get Free Report)

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.